Keyphrases
Fadrozole
100%
Hydrochloride
100%
Postmenopausal Patients
100%
Twice Daily
33%
Breast Carcinoma
33%
Estrogen
16%
Moderate to Severe
16%
Dose Effect
16%
Treatment Group
16%
Androgens
16%
Plasma Concentration
16%
Randomized Phase II Trial
16%
Prospective Randomized Trial
16%
Tumor Regression
16%
Dose Level
16%
Overall Response Rate
16%
Partial Response
16%
Duration of Response
16%
Hormonal Therapy
16%
Twice-daily Dosing
16%
Prior Chemotherapy
16%
Life-threatening
16%
Aromatase Inhibitors
16%
Laboratory Parameters
16%
Heterogeneous Groups
16%
Estrogen Level
16%
Dosing Schedule
16%
Continuation Treatment
16%
Perimenopausal
16%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Carcinoma
100%
Fadrozole
100%
Aromatase Inhibitor
16%
Androgen
16%
Tumor Regression
16%
Hormone Cancer Therapy
16%
Patient History of Chemotherapy
16%
Treatment Group
16%